Product Description
Revefenacin, a once-daily long-acting muscarinic antagonist for nebulization recently approved by the US FDA for the treatment of patients with COPD, was discovered and developed using "duration and lung selectivity-by-design." This strategy selected a molecule with a high lung-selective index to maximize bronchodilation and limit systemic anti-muscarinic side effects. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/31908443/)
Mechanisms of Action: mAChR Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Inhalant,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Egypt | Lebanon | Philippines | Saudi Arabia | Singapore | United Arab Emirates | United States
Approved Indications: Chronic Obstructive Pulmonary Disease
Known Adverse Events: Back Pain | Headache | Pain Unspecified | Nasopharyngitis | Pharyngitis | Respiratory Tract Infections
Company: VIATRIS & KG
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Chronic Obstructive Pulmonary Disease
Phase 2: Respiratory Insufficiency
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| RARICO | P2 |
Recruiting |
Respiratory Insufficiency|Chronic Obstructive Pulmonary Disease |
2024-06-01 |
|
| REV-3001 | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2023-07-26 |
92% |
| CTR20202111 | P1 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
None |
|
| CTR20212308 | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
None |